GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProtoKinetix Inc (OTCPK:PKTX) » Definitions » YoY EBITDA Growth

ProtoKinetix (ProtoKinetix) YoY EBITDA Growth : 100.00% (As of Dec. 2023)


View and export this data going back to 2017. Start your Free Trial

What is ProtoKinetix YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. ProtoKinetix's YoY EBITDA Growth for the quarter that ended in Dec. 2023 was 100.00%.

ProtoKinetix's EBITDA per Share for the three months ended in Dec. 2023 was $0.00.

ProtoKinetix YoY EBITDA Growth Historical Data

The historical data trend for ProtoKinetix's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ProtoKinetix YoY EBITDA Growth Chart

ProtoKinetix Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
YoY EBITDA Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only -220.00 -68.75 70.37 25.00 83.33

ProtoKinetix Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
YoY EBITDA Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -100.00 100.00 100.00 100.00 100.00

ProtoKinetix YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

ProtoKinetix's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (A: Dec. 2023 )
=(EBITDA per Share (A: Dec. 2023 )-EBITDA per Share (A: Dec. 2022 ))/ | EBITDA per Share (A: Dec. 2022 ) |
=(-0.001--0.006)/ | -0.006 |
=83.33 %

ProtoKinetix's YoY EBITDA Growth for the quarter that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (Q: Dec. 2023 )
=(EBITDA per Share (Q: Dec. 2023 )-EBITDA per Share (Q: Dec. 2022 )) / | EBITDA per Share (Q: Dec. 2022 )) |
=(-0--0.002)/ | -0.002 |
=100.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProtoKinetix YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of ProtoKinetix's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

ProtoKinetix (ProtoKinetix) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ProtoKinetix Inc (OTCPK:PKTX) » Definitions » YoY EBITDA Growth
Comparable Companies
PALI SILO CING EMMA LIPO SONN FRTX ALZN SNPX PXMD OCSE:NOVO B VRTX REGN ASX:CSL MRNA XKRX:207940 XKRX:068270 XBRU:UCB XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
412 Mulberry Street, Marietta, OH, USA, 45750
Website
http://www.protokinetix.com
ProtoKinetix Inc is a research and development stage biotechnology company focused on scientific medical research of AFGPs (Anti-Freeze Glycoproteins). The AFGP is a compound produced by fish, insects, reptiles, bacteria, and plants that enable survival in freezing temperatures. The company also develops AFGP applications which include regenerative medicine issues including harvesting, processing, storage, and transplanting cells, tissues, and organs and treatments for chronic inflammatory conditions and diseases caused by stress factors, including UV radiation, oxidation, and cryopreservation and hydrogen peroxide.
Executives
Clarence Edward Smith director, 10 percent owner, officer: President & CEO 1845 COUNTY ROAD #214, ST. AUGUSTINE FL 32084
Michael Richard Guzzetta officer: CFO 412 MULBERRY STREET, MARIETTA OH 45750
Lachlan Grant Young 10 percent owner 6438 ROSEBERY AVE., WEST VANCOUVER A1 V7W2C6
Edward P. Mcdonough director 1226 WASHINGTON AVENUE, PARKERSBURG WV 26101
Susan Marie Woodward officer: CFO 705 DUGAN ROAD, BELPRE OH 45714
Peter Krogh Jensen director 4656 HOSKINS ROAD, NORTH VANCOUVER A1 V7K 2R1
Ian Thomas Gregory director 2225 FOLKESTONE WAY, WEST VANCOUVER A1 V7S 2Y6
Ross Laurence Senior director, officer: CEO PH-3, 5688 DALHOUISE ROAD, VANCOUVER A1 V6T 1W4
Mark L Baum director, officer: President C/O IMPRIMIS PHARMACEUTICALS, INC, 12264 EL CAMINO REAL, SUITE 350, SAN DIEGO CA 92130

ProtoKinetix (ProtoKinetix) Headlines

From GuruFocus

Insider Buying: ProtoKinetix Inc CEO and 10% Owner Clarence Smith Acquires 3,750,000 Shares

By GuruFocus Research • 05-26-2023

Insider Buying: ProtoKinetix Inc CEO and 10% Owner Clarence Smith Acquires 3,750,000 Shares

By GuruFocus Research GuruFocus Editor • 05-25-2023